Lead Sponsor

GE Healthcare

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•The subject has been diagnosed with at least one solid primary or metastatic tumor greater than 2.0 cm in diameter, including but not limited to NSCLC, RCC, GBM, melanoma, sarcoma, breast and H\&N cancers.
•The subject has received clinical routine imaging diagnostic work-up within 8 weeks prior to the first \[18F\]AH111585 PET scan.
•The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care.

•The subject has known hyper- or hypo-coagulation syndromes.
•The subject has received chemotherapy within 3 weeks, or received radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to the first \[18F\]AH111585 PET scan.
•The subject is scheduled to undergo chemotherapy, radiotherapy, surgery or any other treatment against cancer between the first and second \[18F\]AH111585 PET scans.
•The subject is scheduled to undergo biopsy for the target tumour between the first and second \[18F\]AH111585 PET scans.
•The subject has intra-hepatic tumour(s) only.
•For the immuno-histochemistry group, the subject's target tumour has been biopsied less than or equal to 1 week prior to the first \[18F\]AH111585 PET scan.

Related studies

NCT04570423 · Solid Tumors, Lymphoma

NCT07489378 · Very Rare Tumors, Very Rare Cancers, and more

NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more

NCT05671510 · Non Small Cell Lung Cancer

NCT07177937 · Small Cell Lung Cancer, Melanoma, and more

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection